Brought to you by 
Series B for Taligen Therapeutics to bring in $65mm
22 Mar 2012
Executive Summary
Taligen Therapeutics (candidates that regulate excess activation of the complement system) has raised $7.1mm out of a potential $65mm tranched Series B financing. First-time backers Alta Partners and Clarus Ventures, which each contribute a new board member, led and were joined by returning shareholders including Sanderling Ventures, Tango Ventures, and High Country Venture. The company will use the money to move its preclinical antibody fragment TA106 (asthma and AMD) and recombinant Factor H (choroidal neovascularization, inflammatory arthritis, ischemia-reperfusion injury, stroke, and spinal cord injury) into human testing.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B for Taligen Therapeutics to bring in $65mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice